Skip to main content
Ipsen Home Page
Press shift tab to select search category
Loading...
  • Newsroom arrow down
      < Back
    • Newsroom
    • Press Releases
    • Media Updates
    • Media Resources
    • Media Contacts
    • Subscribe
  • Investors arrow down
      < Back
    • Investors
    • Investors
    • Financial Results
    • Annual Reports & Regulated Information
    • Investor Events & Financial Calendar
    • Shareholder Information
    • Subscribe
    • Ratings & Bonds
  • Careers arrow down
      < Back
    • Careers
    • Careers
    • Working at Ipsen
    • Culture
    • Job Search
  • Contacts arrow down
      < Back
    • Contacts
    • Contacts
    • Our Locations
    • Report Side Effects
    • Subscribe
  • Press shift tab to select search category
    Loading...
  • English  EN     Français  FR     EN  arrow_down
    • English EN
    • Français FR
  •  Global
    < Back
    • Global EN FR
    • Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • Middle East & Africa
    • United States
    • Brazil
    • Canada
    • Mexico
    • Australia
    • China
    • Singapore
    • South Korea
    • Japan
    • Belgium
    • Ukraine
    • UK
    • Germany
    • France
    • Nordics
    • Greece
    • Italy
    • Netherlands
    • Spain
    • Poland
    • Russia
    • Czech Republic
    • Switzerland
    • Austria
    • UAE & Gulf
    • Saudi Arabia
  • Home
  • Company
      < Back
    • Company
    • Company
    • Leadership
    • History
    • Fondation Ipsen
  • Expertise
      < Back
    • Expertise
    • Oncology
    • Rare Disease
    • Neuroscience
    • Medicines
  • Science
      < Back
    • Science
    • Science
        < Back
      • Science
      • Oncology
      • Rare Disease
      • Neuroscience
    • Profiles
    • Partnering
        < Back
      • Partnering
      • Therapeutic focus
      • Meet the team
    • Clinical Trials
        < Back
      • Clinical Trials
      • Lay Summaries
      • Find Clinical Trials
    • Pipeline
  • Sustainability
      < Back
    • Sustainability
    • Sustainability
    • Environment
    • Patients
    • People
    • Governance
    • Our Standards
  • Patients
      < Back
    • Patients
    • Patients
    • Together for Oncology
    • Together for Rare Disease
    • Together for Neuroscience
    • Collaborate with us
  • Stories
  1. Home
  2. Investors
  3. Regulated Information

Regulated Information

  • Regulated Information
  • Shareholders Meeting

Period

recent search

Reset

Showing: 1 – 05 of 167 Regulated Information

28 July 2022

28 July 2022

Download Ipsen publishes its 2022 half year financial report
Share On Social Media
Share on LinkedInLinkedIn Share on FacebookFacebook
Ipsen publishes its 2022 half year financial report

26 July 2022

26 July 2022

Download Share buyback program – Ipsen reporting from 18 July to 22 July 2022 – Detailed
Share On Social Media
Share on LinkedInLinkedIn Share on FacebookFacebook
Share buyback program – Ipsen reporting from 18 July to 22 July 2022 – Detailed

19 July 2022

19 July 2022

Download Share buyback program – Ipsen reporting from 11 July to 15 July 2022 – Detailed
Share On Social Media
Share on LinkedInLinkedIn Share on FacebookFacebook
Share buyback program – Ipsen reporting from 11 July to 15 July 2022 – Detailed

06 July 2022

06 July 2022

Download Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF
Share On Social Media
Share on LinkedInLinkedIn Share on FacebookFacebook
Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF

06 July 2022

06 July 2022

Download Ipsen – Half year statement – 2022 06 30
Share On Social Media
Share on LinkedInLinkedIn Share on FacebookFacebook
Ipsen – Half year statement – 2022 06 30

1 … 28 29 30 31 32 33 34

IPN price

€162.90

 €-2.50 (-1.51%)

  • Media Resources
  • Annual Report
  • Contacts
  • Our Locations
Ipsen logo
LinkedIn Instagram Facebook Youtube
  • Terms and Conditions
  • Cookie Policy
  • Global Privacy Policy

© Ipsen Pharma. All rights reserved - 2026

You are now leaving the Ipsen group global website. To continue, please click on Continue?

Continue